Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213341 | 0.79 | L3MBTL3 (0.36) | HRH3KCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL13300973 | 0.74 | HRH3 (0.43) | HRH3KCNH2PHGDHMGLLALDH1A1 | |
| SCHEMBL20096193 | 0.72 | HRH3 (0.46) | HRH3KCNH2PHGDHMGLLPOLB | |
| SCHEMBL17692976 | 0.72 | HRH3 (0.46) | HRH3KCNH2PHGDHMGLLPOLB | |
| SCHEMBL3331880 | 0.72 | HRH3 (0.33) | HRH3KCNH2 | |
| SCHEMBL18922961 | 0.68 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL27007335 | 0.68 | HRH3 (0.39) | HRH3KCNH2PHGDHMGLL | |
| SCHEMBL20016532 | 0.68 | SIGMAR1 (0.43) | HRH3KCNH2PHGDHMGLL | |
| SCHEMBL129315 | 0.67 | — | — | |
| SCHEMBL26489 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103172589-A | Thiazolyl-dihydroquinazolines | BOEHRINGER INGELHEIM INT | 2013-06-26 | — | — | CN | disclosed |
| EP-2018385-B1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INT (DE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2018385-B1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INT (DE) | 2013-05-15 | — | — | EP | disclosed |
| CN-101460505-B | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INT | 2013-03-20 | — | — | CN | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| CN-101460505-A | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INT (DE) | 2009-06-17 | — | — | CN | disclosed |
| EP-2018385-A1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007115929-A1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007115929-A1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | HRH3 421/4885KCNH2 1346/4885PHGDH 2362/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | HRH3 359/4885KCNH2 1682/4885PHGDH 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.